Advanced Prostate Cancer – Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis, and treatments of prostate cancer.

Published Sun, 1 Nov 2020
E CourseProstate CancerOncologyNm P CaM P CaCRPC
Organiser European School of Urology
Duration Approx. 60 – 90 minutes

This course series contains five courses, each of them addresses an important topic in diagnosis, treatment, and management of prostate cancer. Each course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 1 to 3 European CME credits (ECMEC). The five courses are:

Course 1: Basis of ADT (published in March 2020)
Course 2: Non-Metastatic Hormone-Sensitive PCa (published in Mar 2022)
Course 3: Metastatic Hormone-Sensitive PCa (published in June 2020)
Course 4: Non-metastatic Castration-Resistant PCa (published in November 2020)
Course 5: Metastatic Castration-Resistant PCa (published in Jan 2021 )

This course Non-Metastatic Castration-Resistant Prostate Cancer is the fourth part of the course series.

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

This series of five e-courses aims to provide HCPs with a complete view of the management of Advanced Prostate Cancer. Users of this training are expected to progress their knowledge in the clinical aspects and management of prostate cancer. Specific learning objectives are as follows:

  • Definition of Hormone sensitive nmPCa / nmPCa / MPCa / CRPC and classification
  • Information about diagnostic tools, how to combine them and the value of their results
  • Information on prognosis factors, predictive factors and patient stratification
  • Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
  • Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
  • Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients


Chapter 1: Definition and occurrence
Chapter 2: Clarifying metastasis and progression
Chapter 3: Predicting outcomes: the role of PSA-DT
Chapter 4: Treatment

At a glance

  • Last update: Feb 2024
  • Publication date: November 2020
  • Available languages: English
  • Topic: Prostate cancer
  • Duration: 60-90 minutes approximately
  • CME: 1 European CME credits (ECMEC)

Contributing Authors

Main author:
Prof. Dr. N. Mottet (Chair of the EAU PCa Guidelines Panel)

Contact our organiser

European School of Urology